



03 July 2019


Dear Healthcare Professional

Additional Supply of FluQuadri

There has been an unprecedented demand for seasonal influenza vaccines this year and this has resulted in a limited availability of influenza vaccines. To address the increase in demand, Sanofi has imported additional doses of FluQuadri for individuals aged 3 years and over. Given that the imported batch (UJ172AB) is packaged using the Standard International labelling, it does not comply with the New Zealand labelling requirements. It is important to note that the product is the same, the differences that we are noting here are in the labelling and we are writing to you to ensure that you are aware of these differences.

The Standard International labelling is intended for the global market and hence is different to the labelling approved for use in New Zealand, as highlighted below:

<p>New Zealand labelling</p> <p>FluQuadri 0.5 mL 3 years & over English</p>	<p>Standard International labelling</p> <p>FluQuadri 0.5 mL 3 years & over English and Spanish</p>
<p>Front panel carton</p> 	<p>Front panel carton</p> 



The package leaflet available in each carton is written in English and Spanish. It states that FluQuadri is approved for use in persons 6 months of age and available in both 0.25 mL and 0.5 mL presentations (as is the case in some international markets). You should note that FluQuadri batch UJ172AB should not be used in children aged 6 to 35 months population.

Should you have any questions relating to this product, please call Sanofi Pasteur Medical Information at 0800 283 684.

Thank you for your understanding.

Regards,

Dr. Christian T. Felter, MD
 Head of Medical, Sanofi Pasteur Australia and New Zealand